Full hydrodynamic reversibility of the weak dimerization of vancomycin and elucidation of its interaction with VanS monomers at clinical concentration by Phillips-Jones, Mary K. et al.
Phillips-Jones, Mary K. and Lithgo, Ryan and Dinu, Vlad 
and Gillis, Richard B. and Harding, John E. and Adams, 
Gary G. and Harding, Stephen E. (2017) Full 
hydrodynamic reversibility of the weak dimerization of 
vancomycin and elucidation of its interaction with VanS 
monomers at clinical concentration. Scientific Reports, 7 
(12697). pp. 1-10. ISSN 2045-2322 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/47166/1/s41598-017-12620-z.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
1SCientifiC REPoRTS | 7: 12697  | DOI:10.1038/s41598-017-12620-z
www.nature.com/scientificreports
Full hydrodynamic reversibility 
of the weak dimerization of 
vancomycin and elucidation of its 
interaction with VanS monomers at 
clinical concentration
Mary K. Phillips-Jones  1, Ryan Lithgo2, Vlad Dinu2, Richard B. Gillis  2,4, John E. Harding3, 
Gary G. Adams  2,4 & Stephen E. Harding2
The reversibility and strength of the previously established dimerization of the important glycopeptide 
antibiotic vancomycin in four different aqueous solvents (including a medically-used formulation) 
have been studied using short-column sedimentation equilibrium in the analytical ultracentrifuge and 
model-independent SEDFIT-MSTAR analysis across a range of loading concentrations. The change in 
the weight average molar mass Mw with loading concentration was consistent with a monomer-dimer 
equilibrium. Overlap of data sets of point weight average molar masses Mw(r) versus local concentration 
c(r) for different loading concentrations demonstrated a completely reversible equilibrium process. At 
the clinical infusion concentration of 5 mg.mL−1 all glycopeptide is dimerized whilst at 19 µg.mL−1 (a 
clinical target trough serum concentration), vancomycin was mainly monomeric (<20% dimerized). 
Analysis of the variation of Mw with loading concentration revealed dissociation constants in the range 
25-75 μM, commensurate with a relatively weak association. The effect of two-fold vancomycin (19 µg.
mL−1) appears to have no effect on the monomeric enterococcal VanS kinase involved in glycopeptide 
resistance regulation. Therefore, the 30% increase in sedimentation coefficient of VanS on adding 
vancomycin observed previously is more likely to be due to a ligand-induced conformational change of 
VanS to a more compact form rather than a ligand-induced dimerization.
Vancomycin (monomer molar mass = 1449 Da) is a member of the glycopeptide family of antibiotics and a ‘last 
resort’ therapy against life-threatening infections caused by Gram-positive bacteria unresponsive to other anti-
biotics1,2. It is a glycosylated heptapeptide consisting of N-methyl-D-leucine, m-chloro-β-hydroxy-D-tyrosine 
(2 molecules), 1-asparagine, p-(2-[α-4-L-epi-vancosaminyl]-β-1-D-glucosyl)-D-phenylglycine, 
p-hydroxy-D-phenylglycine and m,m-dihydroxy-L-phenylglycine. The vancosamine – glucose disaccharide is 
linked to the para-position of the phenyl group of the phenylglycine at position 4 in the heptapeptide. The side 
chains of the heptapeptide backbone are extensively cross-linked including covalent cross-links between pairs 
of amino acids resulting in a tricyclic structure and a rigid framework with a concave pocket along the peptide 
backbone3,4 (Fig. 1).
Vancomycin and related glycopeptide antibiotics inhibit bacterial cell wall biosynthesis by binding to the 
–peptidyl-D-Ala–D-Ala peptide of the muramyl pentapeptide of peptidoglycan precursor known as Lipid 
II. Vancomycin binding has been previously shown to result in inhibition of transpeptidase and transglyco-
sylase activities, affecting the crosslinking process in growing peptidoglycan, formation of glycan chains and 
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incorporation of peptidoglycan precursors leading to osmotic shock and cell lysis4–7. Extensive study of how 
vancomycin binds to Lipid II has been undertaken, yet currently there still remain important questions about 
the nature of the biologically relevant form of glycopeptide antibiotics. Nieto & Perkins5 first reported the aggre-
gation of vancomycin in aqueous solution and these workers used circular dichroism to determine a (molar) 
dimerization constant K2 of 800 M−1. Dimerisation was confirmed by crystal structural data8. NMR spectroscopy 
studies reported K2 values for back-to-back dimers of different glycopeptides in solution of 300 - 700 M−1 9 and 
700 – (6.6 × 106) M−1 3,10. However, most studies have focused on the glycopeptide form in the presence of the 
ligand. For example, using model cell wall precursor peptides such as N-acetyl-D-Ala-D-Ala, binding studies in 
aqueous solution have established that for many glycopeptides, binding is accompanied by increased formation 
(1-2 orders of magnitude11) of asymmetric, back-to-back homodimers9,12–14 mediated by sugar-sugar recogni-
tion9,15. It has been suggested that dimerization enhances the activity of the antibiotic and this is supported by 
the findings that dimerization and binding of D-Ala−D-Ala in vitro are generally cooperative phenomena3. For 
example, dimerization of eremomycin was shown to enhance the affinity of the antibiotic by a factor3 of 10. It 
has been proposed that the dimer binds two adjacent cell wall precursors and that binding to D-Ala−D-Ala at 
one site on the glycopeptide dimer anchors the dimer to the cell wall and thereby enhances the second binding 
event through the chelate effect resulting in a stabilised complex3. Although vancomycin dimerization is gener-
ally considered to be in a back-to-back configuration, crystal structural information of vancomycin in complex 
with N-acetyl-D-alanine revealed the existence of both back-to-back and face-to-face dimers, though the rel-
ative importance of each these configurations in antimicrobial action and affinity remains to be established16. 
Molecular dynamic simulations based on NMR data confirmed the possibility of spontaneous formation of 
both back-to-back and face-to-face dimers and the authors suggested a functional significance for face-to-face 
dimerization3. The crystal structural data also demonstrated higher order oligomerisation for vancomycin in the 
presence of ligand such as dimer-to-dimer and trimers of dimers, mediated by face-to-face and side-side interac-
tions17,18. Size exclusion data provided evidence of hexameric vancomycin in aqueous solution, comprising three 
pairs of back-to-back dimers17.
For clinical use, vancomycin is prepared in 0.9% NaCl and infused at a starting concentration of 2.5–5.0 mg.
mL−1 in adults so that antibiotic entry proceeds at no more than 10 mg.min−1 in order to minimise undesirable 
side effects of the antibiotic; the aim is to obtain a serum peak level of 25 - 40 µg.mL−1 (8 x minimum inhibitory 
concentration (MIC) value), a trough serum concentration (TSC) maintained at 15–20 µg.mL−1 and an initial 
elevated TSC of 20 µg.mL−1 for severe infections19,20.
Using the powerful matrix-free technique of sedimentation equilibrium in the analytical ultracentrifuge, the 
recently available model-independent SEDFIT-MSTAR algorithm and other advanced analysis due to Roark and 
Yphantis and Kegeles and Rao we now study the reversibility and strength of dimerization of vancomycin in 
four different aqueous solvents (a) 10 mM HEPES buffer, pH = 7.9, (b) 10 mM HEPES buffer supplemented with 
100 mM NaCl, pH = 7.9, (c) 10 mM HEPES buffer supplemented with 100 mM NaCl and 20% glycerol, pH = 7.9 
and finally (d) the medically used formulation of 0.9% NaCl (150 mM) referred to above. To maximize sample 
Figure 1. Chemical structure of vancomycin. The disaccharide composed of vancosamine and glucose 
(purple) is attached at the para-position of the phenyl group of (2-[α-4-L-epi-vancosaminyl]-β-1-D-glucosyl)-
D-phenyl glycine (with residue 4). Also shown are residue 1 (green): N-methyl-D-leucine; residue 2 (light 
orange): m-chloro-β-hydroxy-D-tyrosine; residue 3 (red): asparagine; residue 5 (grey/green): p-hydroxy-D-
phenylglycine; residue 6 (pink): m-chloro- β-hydroxy-D-tyrosine; and residue 7 (dark orange): m,m-dihydroxy-
L-phenylglycine. Black dotted lines highlight the groups that hydrogen bond with the D-Ala-D-Ala substrate in 
peptidoglycan. Redrawn from ref.16.
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stability, short solution columns and the Kegeles-Rao method of analysis of the strength of the interactions based 
on whole-cell weight average molar masses at a low temperature of 7.0 °C were successfully employed.
In addition, in a recent study21 the monomeric state in solution of the enteroccocal A-type VanS histidine 
kinase (HK) was established by sedimentation equilibrium in the analytical ultracentrifuge (confirmed later by 
SEC-MALS22). VanS is a sensor kinase and part of a signal transduction cascade leading to activation of vanco-
mycin resistance genes21,22. Sedimentation velocity in the analytical ultracentrifuge (in the presence of 10 mM 
HEPES buffer supplemented with 100 mM NaCl and 20% glycerol to ensure stability) showed that VanS had 
an extended conformation in solution, of aspect ratio ~ (12 ± 2). In Phillips-Jones et al.21 the addition of circa 
two-fold (in molar terms) vancomycin led to a 30% increase in sedimentation coefficient of VanS. Two possible 
explanations were provided:
 1. Ligand-induced dimerization. The addition of vancomycin leads to a dimerization of VanS, or
 2. Ligand-induced conformation change. The addition of vancomycin leads to a conformation change resulting 
in a decrease in asymmetry from ~12:1 to about 5:1.
We now ascertain using sedimentation equilibrium which of these explanations (1) or (2) applies, and con-
sider the consequences of this finding, including at clinically-relevant concentrations.
Results
Vancomycin self-association. Sedimentation equilibrium in the analytical ultracentrifuge was performed 
at 47500 rpm (~170,000 g) at a temperature of 7.0 °C in the aqueous solvents (a)–(d) as described above. Analytical 
ultracentrifugation is a matrix free (no column of separation medium required) technique for the hydrodynamic 
characterisation of macromolecules. Although vancomycin is too small for the accurate application of sedimen-
tation velocity (formation of a sedimentation boundary from which a distribution of sedimentation coefficients 
can be obtained) – speeds well in excess of the current limit of 60000 rpm would be required - it is still within the 
range for sedimentation equilibrium. Sedimentation equilibrium concentration profiles c(r) vs r, where c(r) is 
the concentration at radial position r (cm) from the centre of rotation gives a direct measure of molecular weight 
(molar mass g/mol) unaffected by conformation. For mixtures of more than one component, it gives principally 
the average molar mass (principally the weight average from concentration distributions recorded using Rayleigh 
interference optics) either over the whole distribution in the ultracentrifuge cell Mw, or as a function of radial 
position Mw(r). Because of the small size of the vancomycin and concentration range being studied (0.6 - 10 mg.
mL−1) no correction for thermodynamic non-ideality was deemed necessary23.
We employ both the M* method of Creeth and Harding24 and the ‘Hinge point’ method25 both implemented 
in the SEDFIT-MSTAR algorithm of Schuck, Harding and coworkers25 to obtain Mw at a series of ultracentri-
fuge cell loading concentrations c (g. mL−1). An example is given in Fig. 2 for vancomycin in 0.9% NaCl (ionic 
strength I = 0.15 mol. L−1), at a loading concentration of 1.25 mg/ml and temperature of 7.0 °C. Figure 2a gives 
the concentration distribution (after correction for baseline effects and the meniscus concentration) and Fig. 2b 
the corresponding ln c(r) vs r2 plot. Figure 2c shows how the integral function M* function progresses along the 
c(r) curve and homes in on the weight average molar mass over the whole distribution Mw: when the cell base is 
reached (r = b) the M* function M*(r → b) = Mw. A value of (2.4 ± 0.1) kDa is returned, a value in excess of the 
monomer molar mass due to self-association. Figure 2d shows the variation in the point weight average molar 
masses Mw(r) which increases with c(r) due to self-association. This plot also permits an estimate of the point 
weight average molar mass at the “hinge point”, rhinge the radial position in the cell where the local concentration 
c(r) = the original loading concentration c, and hence since Mw(rhinge) = Mw the weight average molar mass for 
the whole distribution. A value of (2.4 ± 0.1) kDa is obtained, in agreement with the value from the M* method.
The results are shown for the four different solution conditions combined in Fig. 3, and separately in Fig. 4. 
The results are all consistent with a monomer-dimer equilibrium extrapolating to a monomer molar mass of ~ 
1500 Da (g.mol−1), with a suggestion of some further association beyond that above 5 mg.mL−1 in the presence 
of added NaCl.
Reversibility of vancomycin dimerization. The reversibility of the dimerization can be assessed from 
overlaying plots of the local or “point” weight average molar masses Mw(r) as a function of local concentration 
(in fringe displacement units) c(r) at individual radial displacements r in the ultracentrifuge cell (Figs 2 and 5). 
For a fully reversible system the profiles must overlay26,27 and (allowing for noise at lower concentrations) this 
appears to be the case for all solvent conditions (a)–(d) studied (Fig. 5). Similar behaviour is seen for example for 
an electron transfer flavoprotein28 and an aminocellulose29. Further examples are given in reviews by Harding & 
Rowe30 and Teller31 - see also supplementary data of ref.29. These contrast for example with the case for a mucin 
glycoprotein32. Of clinical relevance, at 5 mg.mL−1 (a clinically important concentration for infusion), ~100% 
of vancomycin is dimerized (Figs 3–5). As with Figs 3 and 4, the data also indicates that for loading concentra-
tions > 5 mg/mL the association may go further than dimerisation, though higher state complexes have so far 
only been reported in the presence of binding ligands4,17,18.
Assessment of association/ dissociation constants for vancomycin dimerization. Now that full 
reversibility has been established we can now assess the strength of the dimerization in terms of the association 
(dimerization) constant k2 (mL.g−1) or the corresponding molar quantity K2 (mL mol−1 or l mol−1 ≡ M−1) and 
molar dissociation constant Kd (M) = 1/K2, from the variation of Mw with c. Following Kegeles and Rao33 and 
equation III-66 of ref.27, for a fully reversible thermodynamically ideal dimerisation:
www.nature.com/scientificreports/
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Figure 2. Sedimentation equilibrium SEDFIT-MSTAR25 output for analysis of vancomycin. Solvent: 0.9% 
NaCl at 7.0 °C at a loading concentration of ~1.25 mg.mL−1 in conventional (12 mm) path length cells. (a) 
concentration (fringe displacement units) versus radial displacement from the centre of rotation, r (b) log 
concentration versus the square of the radial displacement (c) extrapolation of the M* function to the cell base 
to yield the “whole distribution” weight average (apparent) molar mass Mw,app = (2.4 ± 0.1) kDa; (d) plot of the 
point average apparent molar mass (local molar mass) Mw,app(r) – obtained by taking the derivative of the data 
from plot (b) versus local concentration c(r) in the analytical ultracentrifuge cell. The value at the hinge point25 
(where c(r) = the cell loading concentration) – dashed line - yields another estimate for the whole distribution 
Mw,app ~ (2.4 ± 0.1) kDa. Because of the low molar mass and low concentration, non-ideality effects will be 
negligible and Mw,app = Mw.
Figure 3. Change of weight average molar mass Mw of vancomycin with concentration. From sedimentation 
equilibrium analysed by SEDFIT-MSTAR for four different solvent data sets. Squares: 10 mM HEPES. 
Diamonds: 10 mM HEPES + 100 mM NaCl. Up triangles: 10 mM HEPES = 100 mM NaCl + 20% (v/v) glycerol. 
Down triangles: 0.9% NaCl in deionised, distilled water. Solid symbols – molar masses Mw,app obtained from M* 
analysis. Open symbols – molar masses obtained from hinge point analysis25. Because of the low molar masses, 
non-ideality effects can be assumed to be negligible and Mw,app = Mw. Solid line is a standard French curve fit to 
the data.
www.nature.com/scientificreports/
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Figure 4. Comparison of the effects of different solvent conditions on the molar mass -concentration 
behaviour. As Fig. 3 but datasets for each of the solvent conditions shown separately. (a) 10 mM HEPES. (b) 
10 mM HEPES + 100 mM NaCl. (c) 10 mM HEPES = 100 mM NaCl + 20% glycerol. (d) 0.9% (w/v) NaCl in 
deionised, distilled water.
Figure 5. Diagnostic sedimentation equilibrium plots confirming a completely reversible dimerization. 
Weight average molar mass values Mw(r) at individual radial positions in the ultracentrifuge cell plotted against 
local concentration c(r) in interference fringe units for different concentrations: violet (0.625 mg.mL−1), blue 
(1.25 mg.mL−1), green (2.5 mg.mL−1), orange (5.0 mg.mL−1) and red (10.0 mg.mL−1). (a) 10 mM HEPES. (b) 
10 mM HEPES + 100 mM NaCl. (c) 10 mM HEPES = 100 mM NaCl + 20% glycerol. (d) 0.9% NaCl in deionised, 
distilled water. For a completely reversible self-association the plots should lie, within experimental error on the 
same curve shown as a standard French curve fit to the data.
www.nature.com/scientificreports/
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with M1 the monomer molar mass ( = 1449 Da or g.mol−1). Plots of Y(c) versus c for the four different solvent con-
ditions (a)–(d) are given in Fig. 6, and the corresponding values for k2, K2 and Kd for vancomycin dimerization are 
given in Table 1. For these evaluations we have used the Durchschlag-Zipper method for the evaluation of partial 
specific volumes from the atomic composition34 and assumed this does not appreciably change across the range 
of ionic strengths studied (0.01–0.15 mol L−1) nor for the addition of glycerol. These assumptions are considered 
below. Corresponding ‘affinities’ or standard Gibbs free energies for dimerization ΔG° are also given. All inter-
actions are relatively weak (dissociation constants Kd ~ 25–75 μM, and free energies of association ~ 23 kJ mol−1).
Other studies have reported dimerization constants in the absence of ligand to be in the low millimolar range: 
3.9 × 103 M-1 (Kd ~ 250 µM)35 and 4.7 × 102 M−1 (Kd ~ 2.1 mM)11 and 51 M−1 (Kd ~ 19.6 mM)36. Although the lower 
Kd values obtained in the present study indicate a somewhat stronger self-association than previously reported, 
all studies to date (including our own) overall indicate only a weak dimerization, even though dimerization has 
been considered by some to be clinically important for antibiotic activity3,4,9,10,14–16.
Elucidation of the nature of the interaction of vancomycin with enterococcal VanS. Having 
established the strength and fully reversible nature of the dimerization of vancomycin we can now elucidate the 
nature of its interaction with enterococcal A-type VanS, an interaction which may lead to triggering of glyco-
peptide resistance gene expression. The existence of the interaction was first shown by a combination of hydro-
dynamics and CD spectroscopy21, and like the vancomycin dimerization, was subsequently shown to be weak 
(Kd ~ 70 μM)22.
In contrast to the reversible monomer-dimer equilibrium for vancomycin, VanS appears to be purely mon-
omeric in aqueous solution21 from sedimentation equilibrium in the analytical ultracentrifuge in the presence 
Figure 6. Kegeles-Rao evaluation of the association constants k2 (mL/g), K2 (M−1), dissociation constant Kd 
(μM) and standard free energy of association ΔG° for the dimerization of vancomycin. Least squares fitting to 
the Kegeles-Rao equation27,33 Y(c) ≡ M1{Mw(c) − M1}/{(2M1 − Mw(c))2} = k2.c. where the Mw(c) are the weight 
average molar masses (averaged over the whole macromolecular distributions) at different loading (a) 10 mM 
HEPES. (b) 10 mM HEPES + 100 mM NaCl. (c) 10 mM HEPES = 100 mM NaCl + 20% glycerol. (d) 0.9% NaCl 
in deionised, distilled water. Lines shown are obtained by least squares analysis. Values are given in Table 1.
Solvent k2 (mL.g−1) K2 (M−1) Kd (μM) ΔG° (kJ.mol−1)
(a) 10 mM HEPES 18400 ± 5000 27600 ± 7900 35 ± 10 −(23.9 ± 1.1)
(b) 10 mM HEPES + 100 mM 
NaCl 13100 ± 4000 20000 ± 6000 50 ± 15 −(23.1 ± 0.7)
(c) 10 mM HEPES + 100 mM 
NaCl + 20% (v/v) glycerol 14500 ± 3200 22000 ± 4000 45 ± 10 −(23.4 ± 0.1)
(d) 0.9% (w/v) NaCl (150 mM) 14400 ± 3600 21000 ± 5200 40 ± 10 −(23.3 ± 0.6)
Table 1. Values from sedimentation equilibrium for the association constants k2 and K2, the dissociation 
constant Kd and “affinities” (standard Gibbs free energy change ΔG°) for the dimerization of vancomycin in 4 
different solvent conditions. Temperature = 7.0 °C.
www.nature.com/scientificreports/
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of HEPES buffer supplemented with 100 mM NaCl and 20% glycerol (i.e. solvent “c” described above), an 
observation confirmed by the independent method of SEC-MALS – size exclusion chromatography coupled to 
multi-angle light scattering22. Phillips-Jones et al.21 also showed using sedimentation velocity in the analytical 
ultracentrifuge, and under the same solvent conditions, that VanS had an extended conformation in solution 
of aspect ratio (12 ± 2). They further reported that a 2-fold (on a molar basis) addition of vancomycin led to a 
30% increase in sedimentation coefficient of VanS. The dissociation constant of ~70 μM (ref.22) would result in 
no detectable change in the molar mass of VanS as a result of binding of the vancomycin, but the significant shift 
in the sedimentation coefficient of VanS could be due to either (1) a ligand induced dimerization or (2) a ligand 
induced conformation change with a decrease in asymmetry (aspect ratio from ~12:1 to ~ 5:1) as noted above 
and in ref.21.
To help us delineate between explanation (1) or (2) we now use sedimentation equilibrium to explore the 
oligomeric state of VanS in the presence of 2-fold vancomycin (19 μg.mL−1). This vancomycin concentration 
is equivalent to the target initial trough serum concentration desired in the clinic of 20 µg.mL−1 and the target 
maintenance level of 15 – 20 µg.mL−1 desired thereafter19,20,37 and therefore chosen here to investigate bacterial 
VanS-vancomycin interactions. Figure 7 (VanS with ligand) gives the comparable SEDFIT-MSTAR set of plots to 
those of Fig. 5 (VanS without the ligand) of Phillips-Jones et al.21. Figure 7a shows the concentration distribution 
c(r) in fringe displacement units as a function of radial position r, Fig. 7b the corresponding plot of lnc(r) vs r2: the 
~ linear nature of this plot is our first indicator of a highly monodisperse solution. The M* extrapolation (Fig. 7c) 
and hinge point estimation methods (Fig. 7d) from this algorithm both give values for the overall weight average 
molar mass for the distribution, Mw = (45000 ± 1000) Da slightly lower than the values obtained in the absence 
of vancomycin, and the monomeric value from mass spectroscopy21 (M = 45765 Da) with no evidence for dimer-
ization. The slightly lower values may reflect the small influence of the 19 μg.mL−1 vancomycin on the weight 
average molar mass values. This can only mean the VanS remains monomeric in the presence of vancomycin and 
explanation #2 now appears the most plausible explanation of the results.
Figure 7. Sedimentation Equilibrium SEDFIT-MSTAR output for analysis of VanS in the presence of 
vancomycin. Solvent: 10 mM HEPES = 100 mM NaCl + 20% glycerol, pH~7.9, I = 0.1 at 7.0 °C at a loading 
concentration of ~0.3 mg.mL−1 (VanS) supplemented with 19 μg.mL−1 vancomycin in long (20mm) path length 
cells. (a) concentration (fringe displacement units) versus radial displacement from the centre of rotation, r 
(b) log concentration versus the square of the radial displacement (c) extrapolation of the M* function to the 
cell base to yield the “whole distribution” weight average (apparent) molar mass Mw,app = (45.0 ± 1.0) kDa; (d) 
plot of the point average apparent molar mass (local molar mass) Mw,app(r) – obtained by taking the derivative 
of the data from plot (b) versus local concentration c(r) in the analytical ultracentrifuge cell. The value at the 
hinge point (where c(r) = the cell loading concentration) – dashed line - yields another estimate for the whole 
distribution Mw,app ~ (45.0 ± 1.0) kDa. Because of the low concentration, non-ideality effects will be negligible 
and Mw,app = Mw.
www.nature.com/scientificreports/
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Discussion
Reversible weak dimerization of vancomycin: Proportion of monomers and dimers at adminis-
tered concentrations. Vancomycin has to be administered at concentrations high enough so as to be effec-
tive but also low enough to minimize the risks of damage to human tissue such as thrombophlebitis (deep vein 
thrombosis) and nephrotoxicity19,20,38–40. In infusion formulations administration doses are typically at 5 mg.mL−1 
or less. This concentration of 5 mg.mL−1 would correspond to ~ 100% dimers (Eq. 1; Figs 3 and 4). However, this 
is substantially diluted in the serum to 15 - 20 μg.mL−1, minimizing the risk of toxicity38,39, however, the present 
study has established that the monomeric form of vancomycin predominates at this concentration: the proportion 
of dimers will be < 20%.
Monomeric nature of VanS. A previous hydrodynamic study demonstrated that the purified intact VanS 
histidine kinase occurs as a monomer under the aqueous solution conditions used in the present study21. The 
monomeric nature of the protein was also found to be the case using the alternative approach of SEC-MALS and 
in the presence of 0.025% n-dodecyl-β-D-maltoside detergent22. Classic prototypical HKs are considered to be 
membrane-bound homodimers that require two cytoplasmic catalytic ATP-binding (CA) domains to achieve 
trans-autophosphorylation (reviewed in ref.41). However, a full structural understanding of the autophospho-
rylation reaction has yet to be elucidated and there are examples of histidine kinases, which deviate from this 
scheme, including those possessing highly dynamic CA domains. For example, autophosphorylation may occur 
in cis, rather than in trans, as documented for the HK853 kinase41. So cis-autophosphorylation occurs by an 
intrasubunit mechanism; that is, the ATP bound in the CA domain of one subunit phosphorylates the histidine 
residue in the same subunit monomer41,42. As VanS has been shown in the present study to occur as a monomer 
in our experimental system, and it has also previously been shown that VanS protein stored in these same condi-
tions possesses strong autophosphorylation activity even in the absence of vancomycin ligand21, it is possible that 
under the conditions of our experiments, VanS performs cis-autophosphorylation reactions.
The versatility and accessibility of monomeric VanS in aqueous solvent makes it a highly suitable model sys-
tem for investigating ligand-induced conformational changes. Under these conditions, monomeric VanS demon-
strates weak interactions with vancomycin21 with a Kd value of 70 µM22. The finding here of a conformational 
compaction of the elongated VanS protein in response to vancomycin addition; that is, a decrease in asymme-
try from ~12:1 to about 5:1, is consistent with one of the conformational responses expected for a HK during 
cis-autophosphorylation (or indeed trans-autophosphorylation), namely, an approach of the C-terminal CA 
domain towards the phospho-accepting histidine in the central DHp (dimerization histidine phosphotransfer) 
domain. Further studies are required to confirm whether or not this is the case following VanS-vancomycin 
interactions and indeed if the situation we observe in aqueous solution occurs similarly within the membrane. 
It is intriguing that under the conditions used in the present study and previously21, that the VanS membrane 
protein remained soluble in the absence of added detergent and that no detectable detergent remained bound 
after dialysis prior to AUC analysis and indeed post-purification (as revealed by mass spectrometry)21. This may 
be attributable to the large soluble non-membrane portion (predicted to be ~90%) of this sensor kinase. This 
feature has been useful (and indeed highly suitable) for our initial AUC-based interrogations (here and in ref.21) 
to characterise VanS conformational changes in simple aqueous solvent. Further studies are now underway to 
determine whether the VanS-vancomycin interactions observed in aqueous solution here also occurs similarly 
within the membrane environment.
Methods
Source of vancomycin. Vancomycin was obtained from Duchefa Biochemie, Haarlem, The Netherlands. 
A partial specific volume ῡ of 0.67 mL g−1 was calculated from the composition (Fig. 1) and equation 4 of 
Durchschlag & Zipper34 which allows for corrections for covolume, ring formation and electrostriction from 
charged groups. This value is in good agreement with the value of 0.69 ml g−1 of Linsdell et al.35 based on amino 
acid and carbohydrate composition. The validity of the Durchschlag-Zipper approach for aqueous systems had 
been confirmed by a systematic comparison of calculated and experimental partial specific volumes of different 
classes of organic and biochemical compounds, including small molecules and polymers of ionic nature34. We 
make the assumption that there is no ionic strength (I) dependence of ῡ in the range studied (I = 0.01-0.15 mM) 
through electrostriction or related effects (see, for example ref.43) and no effect on ῡ through the addition of 
glycerol. Jaenicke and Lauffer44 have shown that the ‘apparent’ partial specific volumes for tobacco mosaic virus 
(TMV) and TMV protein increase by ~ 0.1% and 0.8% respectively (see for example ref.44) in 25% glycerol.
Solution concentrations of vancomycin c (g. mL−1) were determined densimetrically from the relation45
ρ ρ υ ρ= - -c ( )/(1 ) (2)o o
where ρ and ρo are the solution and solvent densities respectively, measured on an Anton-Paar (Graz, Austria) 
digital density meter.
Source of VanS. Purified VanS protein was prepared as described previously21 and dialysed into 10 mM 
HEPES, 100 mM NaCl, 20% glycerol buffer pH 7.9 (HGN buffer). Reaction mixes comprised VanS at a final 
concentration of 5.6 µM (0.256 mg.mL−1) in the presence of either 12.8 µM (0.019 mg.mL−1) (final concentration) 
vancomycin dissolved in 20 mM Tris.HCl pH 8.0 or an equivalent volume of 20 mM Tris.HCl pH 8.0 buffer as 
control. A partial specific volume of 0.747 mL.g−1 was used as previously reported21.
Sedimentation equilibrium in the analytical ultracentrifuge. Sedimentation equilibrium exper-
iments were performed using a Beckman (Palo Alto, CA, USA) Optima XL-I analytical ultracentrifuge 
equipped with Rayleigh interference optics and an automatic on-line data capture system, to record equilibrium 
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concentration distribution profiles. For the characterisation of vancomycin dimerization, standard 12 mm path 
length cells with aluminium epoxy centrepieces were used and loaded with matched 100 μL of solution (solution 
channel) and reference solvent (reference channel). A rotor speed of 47500 rpm was used at a temperature of 
7.0 °C. The rotor speed was found to be optimum for giving an appropriate concentration (fringe) increment 
from meniscus to base (see Fig. 2). Short solution columns – resulting in relatively rapid equilibrium (<48 h) and 
low temperature ensured the stability of the samples. With the short columns solvent redistribution effects were 
negligible. Rinde46 calculations for the redistribution of glycerol (M = 92 Da) show a ratio of concentration at the 
base to meniscus at equilibrium of ~1.04. Long columns or multiple-speed averaging were inappropriate.
Concentration distributions at sedimentation equilibrium were analysed using the model-independent 
SEDFIT-MSTAR procedure of Schuck, Harding & coworkers25 based on the M* function of Creeth and Harding 
(1982)24. Because loading concentrations up to only 10 mg.mL−1 are used, and particularly because of the small 
size of the vancomycin, non-ideality effects (which tend to lead to underestimates of the molar mass) will also be 
relatively small and we make the approximation that apparent weight average molar masses Mw,app are equal to the 
true weight average molar masses Mw (ref.25).
For the characterisation of VanS in the presence of vancomycin we followed the procedure of Phillips-Jones 
et al.21 using the modified long (20mm) optical path length double-sector titanium cells with sapphire windows. 
These were loaded with 140 µL of solution (containing a final protein concentration of 5.6 µM (260 μg.mL−1) 
in the presence of 12.8 µM (19 μg.mL−1) (final concentration) vancomycin as described above), and a match-
ing amount of reference solvent dialysate in the appropriate channels. An equilibrium speed of 25000 rpm was 
employed at a temperature of 7.0 °C to ensure stability over the long time course (96 hours) of the experiment. 
The use of long path length cells meant that low loading concentrations could be used to give a sufficient signal 
(~0.3 mg.mL−1) for records to be interpreted. Although VanS is much larger than vancomycin, at such low con-
centration, non-ideality effects will also be relatively small and we can also make the approximation23,25 that the 
apparent weight average molar mass Mw,app is equal to the true weight average molar mass Mw.
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